Moderna Inc (MRNA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Moderna Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Moderna Inc's ROI in the second quarter of 2026?
Moderna Inc had a negative return on investment (ROI) of -32.89%, due to the net loss of $-3 billion, during the twelve months ending in the second quarter of 2026.
Within the Healthcare sector 382 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3426 to 3514.
In an era marked by unprecedented fluctuations in the pharmaceutical sector and heightened investor scrutiny, Rosen Law Firm, a preeminent global investor rights law firm, has issued a call for action directed at investors of Moderna, Inc. (NASDAQ: MRNA). The firm has urged individuals who purchased securities of Moderna between January 18, 2023, and June 25, 2024, to secure counsel before the critical deadline for filing lead plaintiff motions in a securities class action, which is set for October 8, 2024. The ContextModerna, Inc. a household name synonymous with innovative mRNA technology and the development of one of the leading COVID-19 vaccines, has experienced its share of market ups and downs since its inception. With the healthcare industry constantly evolving, investors eagerly track developments from drug approvals and patent regulations to market expansions. However, alongside these opportunities lie associated risks that can lead to substantial losses. As a result of the volatility, concerns over the potential misrepresentation of the company’s financial health and business practices have emerged. Such uncertainties are not only detrimental to investor confidence but could also lead to breaches of securities laws, spurring legal action. For those who bought into Moderna’s journey during the specified class period, the stakes are increasingly high.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
